LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
Clinical trial NCT06876675 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06876675
- Sponsor
- Peking University Third Hospital
- Status
- ENROLLING_BY_INVITATION
- Study type
- OBSERVATIONAL
- Start date
- 2024-10-15
- Primary completion
- 2025-09-01
- Enrollment
- 167
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.